These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 22210852)

  • 21. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
    Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
    Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of sulphasalazine plus methotrexate in rheumatoid arthritis.
    Islam MN; Alam MN; Haq SA; Moyenuzzaman M; Patwary MI; Rahman MH
    Bangladesh Med Res Counc Bull; 2000 Apr; 26(1):1-7. PubMed ID: 11192489
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence that the strategy is more important than the agent to treat rheumatoid arthritis. Data from clinical trials of combinations of non-biologic DMARDs, with protocol-driven intensification of therapy for tight control or treat-to-target.
    Pincus T; Castrejón I
    Bull Hosp Jt Dis (2013); 2013; 71 Suppl 1():S33-40. PubMed ID: 24219039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity?
    Jurgens MS; Jacobs JW; Geenen R; Bossema ER; Bakker MF; Bijlsma JW; van Albada-Kuipers IA; Ehrlich JC; Lafeber FP; Welsing PM;
    Arthritis Care Res (Hoboken); 2013 Jan; 65(1):88-93. PubMed ID: 22807253
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Indirect and total costs of early rheumatoid arthritis: a randomized comparison of combined step-down prednisolone, methotrexate, and sulfasalazine with sulfasalazine alone.
    Korthals-de Bos I; Van Tulder M; Boers M; Verhoeven AC; Adèr HJ; Bibo J; Boonen A; Van Der Linden S
    J Rheumatol; 2004 Sep; 31(9):1709-16. PubMed ID: 15338488
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modern treatment strategies in rheumatoid arthritis.
    Hetland ML
    Dan Med Bull; 2011 Nov; 58(11):B4320. PubMed ID: 22047935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
    Keystone E; Freundlich B; Schiff M; Li J; Hooper M
    J Rheumatol; 2009 Mar; 36(3):522-31. PubMed ID: 19228659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
    Bakker MF; Jacobs JW; Welsing PM; Verstappen SM; Tekstra J; Ton E; Geurts MA; van der Werf JH; van Albada-Kuipers GA; Jahangier-de Veen ZN; van der Veen MJ; Verhoef CM; Lafeber FP; Bijlsma JW;
    Ann Intern Med; 2012 Mar; 156(5):329-39. PubMed ID: 22393128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of sulfasalazine and methotrexate in 1102 DMARD-naive patients with early RA.
    Lie E; Uhlig T; van der Heijde D; Rødevand E; Kalstad S; Kaufmann C; Mikkelsen K; Kvien TK
    Rheumatology (Oxford); 2012 Apr; 51(4):670-8. PubMed ID: 22157597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy.
    Ten Klooster PM; Oude Voshaar MAH; Fakhouri W; de la Torre I; Nicolay C; van de Laar MAFJ
    Clin Rheumatol; 2019 Oct; 38(10):2727-2736. PubMed ID: 31161488
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis.
    Sandberg ME; Bengtsson C; Källberg H; Wesley A; Klareskog L; Alfredsson L; Saevarsdottir S
    Ann Rheum Dis; 2014 Nov; 73(11):2029-33. PubMed ID: 24818635
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The BeSt story: on strategy trials in rheumatoid arthritis.
    Klarenbeek NB; Allaart CF; Kerstens PJ; Huizinga TW; Dijkmans BA
    Curr Opin Rheumatol; 2009 May; 21(3):291-8. PubMed ID: 19318946
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association with joint damage and physical functioning of nine composite indices and the 2011 ACR/EULAR remission criteria in rheumatoid arthritis.
    Klarenbeek NB; Koevoets R; van der Heijde DM; Gerards AH; Ten Wolde S; Kerstens PJ; Huizinga TW; Dijkmans BA; Allaart CF
    Ann Rheum Dis; 2011 Oct; 70(10):1815-21. PubMed ID: 21813548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting ultrasound remission in early rheumatoid arthritis: the results of the TaSER study, a randomised clinical trial.
    Dale J; Stirling A; Zhang R; Purves D; Foley J; Sambrook M; Conaghan PG; van der Heijde D; McConnachie A; McInnes IB; Porter D
    Ann Rheum Dis; 2016 Jun; 75(6):1043-50. PubMed ID: 27026689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
    Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
    Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.
    Combe B; Logeart I; Belkacemi MC; Dadoun S; Schaeverbeke T; Daurès JP; Dougados M
    Ann Rheum Dis; 2015 Apr; 74(4):724-9. PubMed ID: 24399234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M
    Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.